Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting Podcast Por arte de portada

Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting

Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting

Escúchala gratis

Ver detalles del espectáculo

Acerca de esta escucha

Featuring an interview with Dr Lindsey Roeker, including the following topics:

  • Clinical development of novel Bruton tyrosine kinase (BTK) degraders in therapy for chronic lymphocytic leukemia (CLL) (0:00)
  • Safety of BTK inhibitors in older and frail patients with CLL (3:41)
  • Utility of minimal residual disease-guided treatment with venetoclax/obinutuzumab (9:20)
  • Impact of the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab in CLL (16:32)
  • Utility of acalabrutinib, venetoclax and obinutuzumab for high-risk CLL (23:31)
  • Emerging data with sonrotoclax and zanubrutinib in treatment-naïve CLL (25:16)
  • Sequencing, tolerability and future development involving pirtobrutinib (25:57)
  • Emerging data with the addition of a BTK inhibitor to chimeric antigen receptor T-cell therapy (32:28)
  • Clinical considerations in the management of Richter’s transformation (38:14)
  • Survival outcomes and quality of life for patients with CLL (41:02)
  • Ongoing and future efforts to improve CLL treatment outcomes (45:01)

CME information and select publications
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
Todavía no hay opiniones